NASDAQ:KZIA

Novogen (KZIA) Stock Price, News & Analysis

Novogen logo
$5.49 +0.18 (+3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$5.47 -0.02 (-0.36%)
As of 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Novogen Stock (NASDAQ:KZIA)

Advanced

Key Stats

Today's Range
$5.25
▼
$5.75
50-Day Range
$5.31
▼
$11.88
52-Week Range
$4.86
▼
$17.40
Volume
229,814 shs
Average Volume
234,949 shs
Market Capitalization
$71.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50
Consensus Rating
Moderate Buy

Company Overview

Novogen Limited, now known as Kazia Therapeutics, is an Australian biotechnology company focused on developing therapies for cancer. The company has historically advanced drug candidates aimed at treating tumors with limited treatment options, rather than marketing approved medicines.

Its pipeline has included paxalisib, an investigational drug designed to inhibit the PI3K and mTOR pathways and studied for brain cancers, including glioblastoma. Kazia has also developed other experimental oncology candidates, including cantrixil for ovarian cancer.

The company traces its roots to Novogen, which adopted the Kazia Therapeutics name in 2016. Based in Australia, it has pursued clinical development programs and collaborations that extend beyond its home market. Its programs remain investigational, and availability or development status may change as clinical research progresses.

AI Generated. May Contain Errors.

Novogen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

KZIA MarketRank™: 
3.467601870405 of 5 stars

Novogen scored higher than 69% of companies evaluated by MarketBeat, and ranked 269th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Novogen has a consensus price target of $29.50, representing about 437.3% upside from its current price of $5.49.

  • Amount of Analyst Coverage

    Novogen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Novogen's stock forecast and price target.
    • Percentage of Shares Shorted

      11.26% of the float of Novogen has been sold short.
    • Short Interest Ratio / Days to Cover

      Novogen has a short interest ratio ("days to cover") of 7.92.
    • Change versus previous month

      Short interest in Novogen has recently increased by 10.46%, indicating that investor sentiment is decreasing significantly.
    • Dividend Yield

      Novogen does not currently pay a dividend.

    • Dividend Growth

      Novogen does not have a long track record of dividend growth.

    • News Sentiment

      Novogen has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.
    • News Coverage This Week

      MarketBeat has tracked 2 news articles for Novogen this week, compared to 1 article on an average week.
    • Search Interest

      4 people have searched for KZIA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
    • MarketBeat Follows

      1 people have added Novogen to their MarketBeat watchlist in the last 30 days.
    • Insider Buying vs. Insider Selling

      In the past three months, Novogen insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      1.00% of the stock of Novogen is held by insiders.

    • Percentage Held by Institutions

      30.89% of the stock of Novogen is held by institutions.

    • Read more about Novogen's insider trading history.
    Receive KZIA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Novogen and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    KZIA Stock News Headlines

    Every Starlink dish pays this stock
    There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
    See More Headlines

    KZIA Stock Analysis - Frequently Asked Questions

    Novogen's stock was trading at $6.89 on January 1st, 2026. Since then, KZIA stock has decreased by 20.3% and is now trading at $5.49.

    Novogen shares reverse split on the morning of Monday, October 28th 2024.The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

    Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Novogen investors own include Ideanomics (IDEX), NIO (NIO), Bionano Genomics (BNGO), Mereo BioPharma Group (MREO), NVIDIA (NVDA), Palantir Technologies (PLTR) and Tesla (TSLA).

    Company Calendar

    Today
    11/18/2026
    Fiscal Year End
    6/30/2027

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Industry
    Biotechnology
    Sub-Industry
    Biotechnology
    Current Symbol
    NASDAQ:KZIA
    Previous Symbol
    ASX:KZA
    CIK
    1075880
    Employees
    6
    Year Founded
    1994

    Price Target and Rating

    High Price Target
    $40.00
    Low Price Target
    $18.00
    Potential Upside/Downside
    +437.3%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.78
    Research Coverage
    9 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    N/A
    Quick Ratio
    N/A

    Sales & Book Value

    Annual Sales
    $1.23 million
    Price / Sales
    57.89
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($5.34) per share
    Price / Book
    -1.03

    Miscellaneous

    Outstanding Shares
    12,970,000
    Free Float
    12,839,000
    Market Cap
    $71.21 million
    Optionable
    Optionable
    Beta
    2.34

    Social Links

    10 Best Stocks to Own in Fall 2026 Cover

    AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

    Get This Free Report

    This page (NASDAQ:KZIA) was last updated on 11/18/2026 by MarketBeat.com Staff.
    From Our Partners